Natalia Cenfra

Publications (6)26.62 Total impact

• Article: Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine.

  Angela Rago, Lorenzo Ridola, Miriam Lichtner, Sergio Mecarocci, Raffaella Marocco, Natalia Cenfra, Valeria Belvisi, Claudio M Mastroianni, Giuseppe Cimino
  Journal of Antimicrobial Chemotherapy 11/2011; 67(2):510-1. · 5.07 Impact Factor
• Article: Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene.

  Loredana Elia, Sara Grammatico, Francesca Paoloni, Marco Vignetti, Angela Rago, Natalia Cenfra, Sergio Mecarocci, Marco Mancini, Matteo Luciani, Francesco Di Raimondo, Giovanni Cazzaniga, Mabel Matarazzo, Maria Luisa Moleti, Lidia Santoro, Gianluca Gaidano, Robin Foà, Franco Mandelli, Giuseppe Cimino
  [show abstract] [hide abstract]
  ABSTRACT: We analyzed 12 MLL/ENL positive ALL patients consecutively diagnosed between 1999 and 2009. The MLL/ENL fusion was identified in 4/150 (2.6%), 8/993 (0.8%), and 0/70 of pediatric, adult, and elderly patients, respectively. Eight patients had a WBC count >50 × 10(9) /L. Ten cases had an evaluable immunophenotyping. A B or T precursor ALL occurred in 7 and 3 patients, respectively. Eleven/12 patients (92%) achieved CR. At 48 months, overall survival and event-free survival rates were 73.3% and 67%, respectively. At CR, a parallel RT-PCR evaluation of the MLL/ENL expression was available in 5 cases. Of these latter, 2 tested MLL/ENL-negative and 3 positive. The minimal residual disease molecular monitoring showed that MLL/ENL status did not correlate with outcome. In fact, all the 2 PCR-negative and 1 of the 3 PCR-positive cases relapsed. Further, a MLL/ENL expression, not preceding a relapse, was detected several times during the follow-up of five long-survivors. In conclusion, also in adults, the MLL/ENL fusion identifies a rare leukemic entity with a favorable prognosis. The observed inconsistency between the clinical cure and the presence of detectable MLL/ENL transcript suggests the existence of a MLL/ENL-expressing "preleukemia" stem cells, similar to what demonstrated for the AML1/ETO-positive leukemia setting.
  American Journal of Hematology 08/2011; 86(12):993-7. · 4.67 Impact Factor
• Article: Solitary plasmacytoma of tibia: a possible correlation with younger age.

  Angela Rago, Antonella Miraglia, Sergio Mecarocci, Giovanni Codacci Pisanelli, Caterina Chiappetta, Claudio Di Cristofano, Antonella Scarchilli, Natalia Cenfra, Vincenzo Petrozza, Giuseppe Cimino
  Leukemia research 08/2010; 34(8):e181-2. · 2.36 Impact Factor
• Article: The therapeutic response and clinical outcome of adults with ALL1(MLL)/AF4 fusion positive acute lymphoblastic leukemia according to the GIMEMA experience.

  Giuseppe Cimino, Natalia Cenfra, Loredana Elia, Simona Sica, Mario Luppi, Giovanna Meloni, Marco Vignetti, Francesca Paoloni, Robin Foà, Franco Mandelli
  [show abstract] [hide abstract]
  ABSTRACT: The clinical outcome of 21 adults with ALL1(MLL)/AF4 positive acute lymphoblastic leukemia enrolled in the GIMEMA LAL 2000 trial and of 25 patients entered into the previous 0496 study is reported. LAL 2000 included more intensive consolidation and transplants. Complete remission rates were 90% and 88% in the LAL 2000 and 0496 trials, respectively. Fifteen patients were transplanted (5 autologous, 10 allogeneic). At 36 months, overall and disease free survivals were 32.9%, 31.8%, 28% and 27.3%, in LAL 2000 and 0496 trials, respectively. Relapses remained the main reason of failure occurring in 10 and 16 of the 19 and 22 responding patients. In the LAL 2000 study, 4 relapses were observed before transplant. Thus, ALL1(MLL)/AF4 abnormality characterized a subset of patients with adverse prognosis in which the overall strategy adopted in the LAL 2000 study, rather than transplants per se, failed to improve the patient clinical outcome.
  Haematologica 05/2010; 95(5):837-40. · 6.42 Impact Factor
• Article: Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen.

  Angela Rago, Miriam Lichtner, Sergio Mecarocci, Raffaella Marocco, Natalia Cenfra, Valeria Belvisi, Cosmo Del Borgo, Giuseppe Cimino, Claudio M Mastroianni
  [show abstract] [hide abstract]
  ABSTRACT: Entecavir and tenofovir disoproxil fumarate are potent and effective antiviral drugs that now represent recommended treatment options for chronic HBV infection. However, no or very limited clinical evidence is currently available on these drugs for the management of HBV reactivation in patients with haematological malignancies. Herein, we report a case of HBV reactivation in a patient with non-Hodgkin's lymphoma following a rituximab-based regimen, and who was successfully treated with a combination antiviral treatment including entecavir and tenofovir disoproxil fumarate.
  Antiviral therapy 01/2010; 15(6):929-32. · 3.16 Impact Factor
• Article: An acute promyelocytic leukaemia patient with a new atypical promyelocytic leukemia breakpoint.

  Natalia Cenfra, Fabiana De Cave, Clara Minotti, Emanuela Ghia, Angela Rago, Giovanni Codacci Pisanelli, Daniela Diverio, Giuseppe Cimino
  British Journal of Haematology 07/2008; 142(5):854-6. · 4.94 Impact Factor